Skip to main content

Spruce Biosciences, Inc.

corporate_fare Company Profile

Spruce Biosciences, Inc.

SPRB·NASDAQ·Life Sciences·CIK 0001683553

The company is a biopharmaceutical company that develops and sells new treatments for neurological disorders where current medical options are insufficient. Founded in April 2016, the company's management team has experience in developing and commercializing innovative therapies. The company's strategy includes seeking regulatory approval and maximizing the U.S. commercial potential of TA-ERT for treating Mucopolysaccharidosis Type IIIB (MPS IIIB). They plan to seek U.S. accelerated approval for tralesinidase alfa enzyme replacement therapy ("TA-ERT") for MPS IIIB using existing non-clinical and clinical data. As a condition for a biologics license application ("BLA") from the U.S. Food and Drug Administration ("FDA"), a confirmatory trial will be initiated. If the BLA is approved, the company intends to build a specialized commercial and medical affairs organization to support TA-ERT's commercialization. TA-ERT has received Rare Pediatric Disease Designation, Fast Track Designation, Breakthrough Therapy Designation, and Orphan Drug Designation in the United States and European Union ("EU"). The company aims to commercialize TA-ERT and its other investigational products globally, including North America, the EU, the United Kingdom, Latin America, Turkey, Asia, and other international markets. They plan to establish their own commercial organization in the United States, EU, and the United Kingdom, and seek regional strategic collaborations and third-party distributors in other international markets. The company focuses on serious diseases with significant unmet medical need and clear, well-understood biology.

Spruce Biosciences, Inc. (NASDAQ:SPRB) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 24 items for SPRB at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • FDA BLA for Sanfilippo Drug on Track for Q4 2026; Spruce Biosciences Secures $50M Capital
  • Carlyle Group/Abingworth Reduces Stake Below 5% in Spruce Biosciences
  • Spruce Biosciences Reports Positive Long-Term Clinical Data for TA-ERT in Sanfilippo Syndrome Type B, Paving Way for FDA Approval
  • Spruce Biosciences Secures Up to $50M Debt Facility with Warrants to Extend Runway

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$0
Net Income
-$38.97M
Diluted EPS
-$50.83
Op. Cash Flow
-$33.33M
Operating Income
-$36.51M
Cash & Equivalents
$48.91M
Total Debt
$0
Debt / Equity
0.00×
Shares Outstanding
1.37M sh
Source: 10-K · filed 2026-03-09 · accession 0001193125-26-097558
$38
52-week range · as of 2026-11-09 $38 – $129
Market cap
$109.21M
Volume
108.3K (1.4× avg)
3-mo avg 78.8K
Live data · 2026-11-22 12:47 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed SPRB - Filings & News (Page 2)

SPRB
Mar 09, 2026, 7:05 AM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $58.00
Real-time Price: $38.00 info
Change: -$20.00 (-34%) info
Market Cap: $109.212M info
SPRB
Feb 18, 2026, 5:27 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $53.76
Real-time Price: $38.00 info
Change: -$15.76 (-29%) info
Market Cap: $109.212M info
SPRB
Feb 05, 2026, 4:11 PM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $70.85
Real-time Price: $38.00 info
Change: -$32.85 (-46%) info
Market Cap: $109.212M info
SPRB
Jan 08, 2026, 8:05 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $78.10
Real-time Price: $38.00 info
Change: -$40.10 (-51%) info
Market Cap: $109.212M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets